Regulators in China approved Soliris (eculizumab) for adults with hard-to-treat (refractory) generalized myasthenia gravis (gMG) who test positive…
Margarida Maia, PhD
Science Writer
Margarida Maia, PhD, is a science and medical writer with a background in biochemistry and biomedical sciences. She studied in Portugal and Belgium and has been working in science communication for several years. She has been writing at Bionews since 2021. Her work focuses on explaining new research and medical developments on rare diseases in a clear and accessible way.
Education
- PhD in Biomedical Sciences, VIB & KU Leuven, Belgium
- Degree in Biochemistry, University of Porto, Portugal
Certifications
- Google Project Management: Professional Certificate
Published Works
- Valdez, Y, Maia, M, Conway EM. CD248: Reviewing its role in health and disease. Curr Drug Targets. 2012;13:432–439.
- Maia, M et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 2011;11:162.
- Antunes, R, Brandão, C, Maia, M, Arosa, FA. Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells. Immunol Cell Biol. 2011;89:111–121.
- Maia, M et al. CD248 and its cytoplasmic domain: A therapeutic target for arthritis. Arthritis Rheum. 2010;62:.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
The direct costs of myasthenia gravis (MG) are about four times higher than for the general population and even…
The rate of death from myasthenia gravis (MG) generally increases with age, but it peaks among teenage boys and…
People who develop myasthenia gravis (MG) with very late onset — when they’re age 65 or older — may…
Batoclimab (HBM9161) eased the symptoms of generalized myasthenia gravis (gMG) and their impact on daily function, hitting the main…
The platelet-to-lymphocyte ratio (PLR), which can be readily measured from a simple blood test, may help tell which people with…
The U.S. Food and Drug Administration (FDA) has granted priority review to Argenx’s under-the-skin (subcutaneous) formulation of efgartigimod —…
About one in 10 patients with thymic carcinoma — a rare type of malignant tumor in the thymus gland —…
The cancer immunotherapy Imfinzi (durvalumab) may, in rare cases, trigger myasthenic crises — a serious complication of myasthenia gravis (MG)…
Plasma exchange combined with intravenous, or into-the-vein, immunoglobulin (IVIG) appears to be safe, and better than plasma therapy alone at…